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ABSTRACT  
Nasal delivery is an alternative to oral or parenteral administration due to certain limitations such as absorption of the drug, drug targeting to 
particular organs can cause a problem for administration through oral route.  The nasal route has also been successfully used for bypassing the 
blood-brain barrier and afterword delivering drug molecules to the central nervous system. Also, lag time related to oral drug delivery is 
reduces by this route and offers noninvasiveness, self-medication, patient comfort, and patient compliance. Extend drug delivery can be 
attained by different new dosage forms like in situ gel. In situ formulations are drug delivery systems. The in-situ gelling system is a process in 
which the solution forms of a gel before administration in the body, but once administrated, it undergoes gelation in-situ, to form a gel. In situ 
gelling system becomes very popular nowadays because of their several advantages over conventional drug delivery systems like  a sustained 
and prolonged release of a drug, reduced Frequency of administration, improved patient compliance and comfort. Approaches towards the 
various formulation of in-situ gel concerning temperature, pH, and physicochemical conditions. The in situ gel-forming polymeric formulations 
offer several advantages like sustained and prolonged action reduced Frequency of administration, in comparison to conventional drug delivery 
systems.  From a manufacturing point of view, the production of such systems is less complex and thus lowers the investment and 
manufacturing cost. Various evaluation parameters are considered during the preparation of In-Situ gel. 
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The nasal route is an important mode of drug delivery, with a 
growing number of products available for administration 
through the route for systemic and local administration. An 
in-situ gel is a new dosage form. In situ gel has been applied 
in nasal drug delivery recently.  
Compared with other liquid nasal formulation nasal in-situ 
gels are administered as low viscosity solution into the 
intranasal cavity which upon contact with the nasal mucosa, 
the polymer changes conformation making a gel. So that it 
not only increases the contact time between the drug and the 
absorptive site but also releases the drug slowly in the nasal 
cavity.  
A gel is a state between liquid and solid, which consists of 
physically cross-linked networks of long polymer molecules, 
with liquid molecules trapped within a three-dimensional 
polymeric network swollen by a solvent. Before 
administration, the in-situ gelling system is a liquid aqueous 
solution and it changes into a gel at the physiological 
condition. Prolonged and sustained release of the drug is 
reproducible, and in-situ gel is biocompatible, with 
magnificent stability and reliable quantities of medication, 
making it more accurate.  
There are various routes for in situ gel drug delivery, for, 
example, oral, ocular, vaginal, rectal, intravenous, 
intraperitoneal, etc. Gelation happens through crosslinking 
of the polymer chain, which can be attained through covalent 
bond formation (chemical crosslinking) or non-covalent 
bond formation (physical crosslinking). A different 
mechanism exists which produce the formation of in-situ 
gels, like depend on physiologic stimuli (e.g. temperature 
modifications, pH-triggered systems), those based on 
physical changes in biomaterials (e.g. Solvent exchange and 
swelling), and those depend on chemical reactions (e.g. UV 
radiation, ionic crosslinking and ion activated systems). In 
this system, there is no need for any organic solvents, 
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copolymerization agents, or a directly applied trigger for 
gelation. In-situ gel formulation is carried out for targeted 
delivery through the vaginal and rectal routes, and the nasal 
mucosa, circumventing the hepatic first-pass metabolism, 
which is important for the proteins and peptides delivery 
that is usually administered via the intravenous route 
because of their susceptibility to the gastrointestinal 
protease.(1)(2) 
 NASAL DRUG DELIVERY SYSTEM  
Intranasal delivery mainly offers potentially an alternative 
viable for various drug delivery. It is suitable for the local 
and systemic delivery of diverse therapeutic compounds. 
Hence there have been many investigations involving the 
nasal cavity as a feasible site for the administration of many 
therapeutic agents. It is effective in the treatment of local, 
systematic and CNS sites.  
Local: Intranasal administration of medicines is the natural 
choice for the treatment of topical nasal Disorders. Among 
the most common examples are antihistamines and 
corticosteroids for rhinosinusitis, and nasal decongestants 
for cold symptoms. In these cases, the intranasal route is the 
primary option for drug delivery because it allows a rapid 
symptom relief with less side-effect.  
Systemic: The intranasal administration is an effective way 
to systemically deliver drugs as an alternative to oral and 
intravascular routes. Consequently, by nasal formulations, 
the number of drugs administered intended to achieve 
systemic effects has widely increased. Some prominent 
examples include analgesics [morphine], cardiovascular 
drugs as Propranolol and carvedilol, hormones such as 
levonorgestrel, progesterone and insulin, anti-inflammatory 
agents as indomethacin and Ketorolac, and antiviral drugs 
[acyclovir]. (2) 
ANATOMY AND PHYSIOLOGY OF NOSE  
It is essential to have a clear understanding of the anatomy 
and physiology of the nose and how it relates to the 
characteristics of the delivery system used. In humans and 
other animal species, the major functions of the nasal cavity 
are breathing and olfaction. It also affords an important 
protective activity once it filters, heat and humidifies the 
inhaled air before reaching the lowest airways. The human 
nasal cavity has a total volume of 15-20ml and a total surface 
area of approximately 150cm. The nose is separated in two 
nasal cavities by the septum. The volume of each cavity is 
about 7.5 ml and has a surface area around 75 cm pH of the 
mucosal secretions ranges from 5.0 to 6.7 in children and 5.5 
to 6.5 in adults. The nasal passage epithelium is covered by a 
mucus layer that is renewed every 10 to 15 min. From the 
nose, mucus moves at a rate of 5 to 6 mm/min resulting in 
particle clearance within the nose every 20 min. (2) 
Three regions can be distinguished in each part  
1. Respiratory region: The nasal respiratory region is the 
largest part of the nasal cavity, also called conchae. The 
respiratory region is the most important for systemic drug 
delivery.10-12 The respiratory epithelium is composed of 
four types of cells, namely, non-ciliated and ciliated columnar 
cells, basal cells and goblet cells. The respiratory region 
contains three nasal turbinates: superior, middle, and 
inferior which project from the lateral wall of each of the 
nasal cavity. For systemic drug delivery, nasal respiratory 
mucosa is considered the most important section. 
2. Vestibular region: Most anterior part of the nasal cavity 
is nasal vestibule, just inside the nostrils, and presents an 
area about 0.6 cm this nasal portion is covered by a stratified 
squamous and keratinized epithelium with sebaceous glands 
is responsible for filtering out the airborne particles. It is 
considered to be less important in the three regions 
concerning drug absorption.  
3. Olfactory region: The olfactory region is located in the 
roof of the nasal cavity and extends a short way down the 
septum and lateral wall it is of about 10 cm2 in surface area 
and it plays a vital role in the transportation of drugs to the 
brain and the CSF. When the drug is administered by the 
nasal route, it can enter into the brain by three different 
paths. The first one is the systemic path, by this route the 
drug is absorbed into the systemic circulation and 
subsequently reaches the brain by crossing BBB [especially 
lipophilic drug]. The other pathways are the olfactory region 
and the trigeminal neural pathway by which the drug is 
directly transported from the nasal cavity to CNS 
[cerebrospinal fluid and brain tissue]. There is a different 
mechanism by which the drugs across the olfactory 
membrane reach CNS. The first mechanism involves a direct 
transfer of the drug to primary neurons of the olfactory 
epithelium and transport to the olfactory bulb by 
intracellular axonal transport with subsequent possible 
distribution into more distant brain tissues. The second 
mechanism depends on the drug permeation across the 
olfactory sustentacular epithelial cells, either by transcellular 
or paracellular mechanisms followed by uptake into CNS. 
The last one employs pinocytosis by olfactory neurons. 
(1)(3) 
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ADVANTAGES (ASSOCIATED FACTORS) OF INTRANASAL DELIVER   
Table 1: Advantages of intranasal delivery (4)(5)(2) 
Advantages Factors 
Improving patient 
compliance and convenience 
 
 A trained person not required 
 Needle-free (painless) 
 Non-invasive 
 User- friendly 
 Ease of administration 
 Self-medication possible 
 The nasal route is suitable  when compared with a parenteral route for long term therapy 
 Minimal aftertaste  
 The risk of transmission of infectious  disease is reduces 
Rapid absorption and onset 
of pharmacologic action 
 Highly vascularized mucosa 
 Easy accessibility to blood capillaries  
 Large nasal mucosal surface area  
 Drugs which cannot be absorbed orally may  be delivered by nasal route direct in the 
systemic circulation 
Good penetration  For lipophilic drugs 
 For low molecular weight drugs  
 Bioavailability of larger drug molecules can be increased using absorption enhancer or 
other approaches 
Direct delivery of a drug to 
CNS system 
 Bypass BBB, via olfactory region 
 Useful for local and systemic delivery 
Avoids a harsh environment  Less chemical and enzymatic degradation 
Low dose required  Drug degradation is absent.   
 Avoids the first-pass metabolism 
 Avoids GIT degradation 
 Lower side effects 
 High bioavailability 
 
LIMITATIONS (ASSOCIATED FACTORS) OF INTRANASAL DELIVERY (4)(5)(2) 
Table 2: Limitations of intranasal delivery 
Limitation Factors 
Reduced capacity of nasal absorption means low 
bioavailability 
 Due to pathologic conditions such as cold or allergies, 
which may significantly alter the nasal bioavailability 
 Lack of adequate aqueous solubility. 
Sometimes, the drugs cause irritation and irreversible 
damage of the cilia on the nasal mucosa 
 Due to constituents added in dosage forms 
Defense mechanisms such as mucociliary clearance 
influence permeability of drug 
 An enzymatic barrier to the permeability of drug 
Disrupt and dissolve the nasal membrane  Due to the high concentration of absorption enhancers 
High molecular weight compounds cannot be supplied 
(mass cut off - 1 kDa) 
 The volume of 25–200 ml that can be distributed into the 
nasal cavity is inadequate 
Irreversible administration  Once the drug administered cannot be removed 
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BARRIERS FOR NASAL DRUG DELIVERY  
Major barriers to nasal drug delivery are low bioavailability, 
mucociliary clearances, and enzyme degradation. Some 
important characteristics of different barriers which affect 
the nasal drug delivery are discussed below: 
Low bioavailability: 
 Bioavailability of polar drugs is fundamentally low (about 
10% for low molecular weight drugs and 1% for 
peptides, for example, calcitonin and insulin). 
 Polar drugs have limited nasal absorption with large 
molecular weight.z 
 Drugs can cross the epithelial cell membrane by the 
transcellular and paracellular routes between cells.  
 Polar drugs with a molecular weight below 1000 Da will 
pass the membrane by the latter routes. 
 Nasal absorption of polar drugs is enhanced by the co-
administration of absorption-enhancing agents. 
 Polarity lipophilic: 
1. LMW lipophilic -100% bioavailability 
2. HMW amphipathic -10% bioavailability 
3. Peptides < 1% 
Examples  
 Surfactants (Sodium lauryl sulfate, sodium dodecyl 
sulfate, phosphatidylcholines, Laureth-9) 
 Bile salts (Sodium glycocholate, sodium taurocholate, 
sodium deoxycholate) 
 Fatty acids and their derivatives (linoleic acid) 
 Phospholipids (lysophosphatidylcholine) 
 Various cyclodextrin and cationic compounds like 
chitosan, poly-L-arginine, and poly-L-lysine 
 Fusidic acid derivatives (sodium tauradihydrofusidate) 
Mucociliary clearance: 
 It is an important factor that involves in both combine 
action of mucus and cilia, which fight against inhaled 
foreign particles in the respiratory tract. 
 Drug transportation across the nasal mucosa leads to 
decreases because of high clearance. 
 For liquid and powder formulation which are not 
bioadhesive, the half-life for clearance is of the order of 
15-30 min. 
 To overcome the rapid mucociliary clearance 
bioadhesive excipients are used in the formulation. 
 The clearance may also be decreased by retaining the 
formulation in the anterior and less ciliated part of the 
nasal cavity, thus leading to improved absorption. 
Enzymatic degradation: 
 When peptides and proteins cross the nasal mucosa, 
there are chances of enzymatic degradation of the 
molecule in the lumen of the nasal cavity or during 
passage through the epithelial barrier, which can limit 
the bioavailability of the drug. 
 These two sites contain exopeptidases such as mono 
and diamino peptidases that can cleave peptides at 
their N and C termini, and endopeptidases like serine 
and cysteine, which can attack internal peptide bonds. 
The use of enzyme inhibitors, cosolvents, and prodrugs 
may be the way to overcome this barrier.(4) 
IDEAL DRUG CANDIDATE FOR NASAL DRUG 
DELIVERY  
 The drug should not produces any irritation to the 
nasal mucosa 
 The drug should not cause any side effect  
 The drug should not contain any toxic metabolites 
 The drug should be free from any offensive odor 
 A dose of the drug should be less than 25 mg  
 The drug should puses appropriate nasal absorption 
property 
 Suitable clinical rationale for a nasal dosage form 
 Suitably stable characteristics (2)(6) 
 
PROFILE OF AN IDEAL DRUG CANDIDATE SUITABLE FOR NASAL DRUG DELIVERY SYSTEM (7) 
 
Figure2. Profile of an ideal drug candidate suitable for nasal drug delivery System 
 
Profile of an ideal drug candidate for nasal  drug delivery 
Molecular weight < 500 Da, log P < 5  
Aqueous solubility < 50 mg/ml 
Dose potency < 5mg/dose/spray of puff per nostril 
Drug in solution: pH approximately 5.5, osmolality < 500 mosm/kg 
No nasAal irritation from drug 
No toxic metabolites 
Volume 25-125 µl per nostril 
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MECHANISM OF DRUG ABSORPTION: 
The absorption of the drug from a nasal route for systemic 
or CNS effect occurs when it passes through the mucous 
layers and epithelial membrane before reaching the 
systemic circulation or passes directly to CNS. For systemic 
effect, drug absorption is considered to take place in the 
respiratory region consisting of turbinates and part of the 
nasal septum. The olfactory region, which is next to the 
respiratory region, is the foremost site from where the drug 
can be absorbed directly into the brain for the CNS effects. 
When a drug is given intranasally, a drug can directly reach 
the brain either by direct transport from olfactory region to 
the brain or from the blood (systemic circulation) to the 
brain or through the trigeminal neural pathway by which 
drug partly travels from the nasal cavity to the cerebrospinal 
fluid (CSF). Consequently, the olfactory region of the nasal 
mucosa that provides a direct connection between nose and 
brain which can be exploited for targeting of drug molecules 
acting on CNS in conditions like Alzheimer’s disease, 
Parkinson’s disease, depression, migraine, schizophrenia, 
epilepsy, brain tumors, psychosis, and pain. The absorbed 
drugs must pass from the nasal cavity to the mucus layer. 
This is the initial step of absorption. The drug with small 
particle size can easily pass through this mucus layer but 
larger, charged drug is difficult to pass it. Mucin is the main 
principle protein of the mucus, which tends to bind to the 
solute, hindering the diffusion. In the mucous layer, some 
additional structural changes are possible as a result of 
changes in environment like pH, temperature. Drug 
absorption through the mucosa has a different mechanism. 
They include transcellular (simple diffusion across the 
membrane) and paracellular transport (movement between 
cell and transcytosis by vesicle carriers). Drug absorbed can 
potentially be metabolized before reaching the systemic 
circulation and has a limited residence time in the cavity. 
Different mechanisms, such as passive diffusion 
(transcellular), passive diffusion (paracellular), carrier-
mediated transport, transcytosis, absorption, and efflux 
transport have been used for drug transport through the 
nasal epithelium. Table III discusses some important 
comparisons between the two mechanisms, which are 
widely used in drug transport through the nasal epithelium. 
(4)(7)(1)
 
Table 3: Mechanism of drug passage through the mucus. 
First mechanism (Paracellular process) Second mechanism (Transcellular process) 
• Aqueous route of transport. 
• The process occurs within the cell and transcytosis by 
vesicle carrier 
• This route is slow-moving  and passive 
• It is suited for hydrophilic drugs 
• There is an inverse log-log correlation in between intranasal 
absorption and the molecular weight of water-soluble 
compounds 
• Bio-availability of drugs was observed poor with a 
molecular weight greater than 1000 Daltons. 
• Lipoidal route of transport 
• By an active transport route, drugs can also cross the 
cell membranes with carrier-mediated transport 
through the openings of tight junctions 
• It is a means of the transport of lipophilic 
drugs that show a rate-dependency on their lipophilicity 
• For example, chitosan, a natural biopolymer, opens 
tight junctions between epithelial cells to facilitate drug 
transport. 
 
FACTORS AFFECTING NASAL DRUG DELIVERY 
SYSTEM 
1. Physiochemical properties of a drug  
a) Molecular weight: Nasal delivery of a is expected to 
decrease with an increasing molecular weight of the drug 
molecule. A linear inverse correlation within the 
absorption of drugs and the molecular weight of the drug 
has been reported and the molecular weight of the drug 
is greater than 1000 Da except by using of absorption 
enhancers. With the use of permeation enhancers, good 
bioavability to at least 6000 Daltons can be achieved. (2) 
b) Chemical form: It is an important factor for drug 
absorption. By changing the drug into salt or an ester 
form can change its absorption; e.g. in situ absorption of 
carboxylic acid esters of L-tyrosine was significantly 
greater than that of unmodified L-Tyrosine. (4) 
c) Size: Particle size and morphology of a drug are 
important tools for the design of nasal drug delivery. 
Generally, particles in the 5-10 microns range should be 
deposited in the nostrils. Too fine particles, less than five 
microns may be inhaled into lungs and should be 
avoided for nasal products while particles greater then 
10μm are deposited with the upper respiratory tract. (2) 
d) Solubility: Solubility is not only limited the drug 
absorption, but it can also limit a formulator‟s ability to 
formulate a formulation if the drug is not sufficiently 
soluble in the desired vehicles. From a mechanistic and 
thermodynamic standpoint of view, it is important to 
learn about the relationship between a drug’s saturation 
solubility and its absorption.(2) 
e) Lipophilicity: Lipophilic compounds tend to readily 
cross biological membranes via the transcellular route 
and these compounds can partition into the lipid 
(bilayer) of the cell membrane and diffuse into and 
traverse the cell in the cell cytoplasm. Some examples of 
lipophilic drugs like naloxone, buprenorphine, 
testosterone, and 17a-ethinylestradiol, are completely or 
almost completely absorbed by the nasal route in animal 
models. The permeation of the compound normally 
increases through nasal mucosa by increasing 
lipophilicity. (2) 
f) Pka and partition coefficient: According to the pH 
partition theory, unionized species are absorbed better 
compared with ionized species and the same holds in the 
case of nasal absorption.(2)  
g) Polymorphism: It can affect the rate of drug dissolution, 
solubility, and absorption through biological 
membranes. (4) 
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2. Physicochemical properties of a formulation 
a) Drug concentration, dose, and dose-volume: Drug 
concentration, dose, and dose-volume of administration 
are three interlinked parameters that affect the 
performance of the nasal delivery system. If the drug 
concentration formulation is increasing by increasing 
formulation volume there may be a limit as to what 
extent nasal absorption will drain out of the nasal cavity.  
0.05-0.15ml is the ideal dose volume with an upper limit 
of 0.20ml.(2) 
b) pH and mucosal irritation: In addition to the 
properties of the nasal surface, the pH of the formulation 
can affect a drug’s permeation. Both the pH and pKa of a 
drug are considered to rationalize systemic absorption. 
To avoid nasal irritation, the pH of the nasal formulation 
should be adjusted to 4.5–6.5. By avoiding nasal 
irritation results in obtaining an increase in drug 
permeation and prevents the growth of bacteria. Nasal 
secretions contain lysozyme, which destroys certain 
bacteria at acidic pH. Lysozyme is inactivated and the 
nasal tissue is susceptible to microbial infection under 
alkaline conditions. (4) 
c) Buffer capacity: Nasal formulations are administered in 
little volumes ranging from 25 to 200μL. Hence, nasal 
secretions may change the pH of the administrated dose. 
This can affects the concentration of unionized drugs 
available for the absorption. Therefore, an appropriate 
formulation buffer capacity may be required to maintain 
the pH in-situ. (2) 
d) Solubilizers: Aqueous solubility of the drug is always a 
limitation for nasal drug delivery in solution. Co-solvents 
are used for increasing solubility like glycols, alcohol, 
Transcutol, medium-chain glycerides and Labrasol can 
be used to enhance the solubility of drugs. (2) 
e) Preservatives: Nasal formulations mostly contain 
preservatives to protect them from microbial 
contamination. Some generally used preservatives are 
parabens, benzalkonium chloride, and benzoyl alcohol. 
Preservatives are used in small quantities and are not 
likely to affect drug absorption (2) 
f) Antioxidants: Antioxidants have not any effect on drug 
absorption or cause nasal irritation. Example- sodium 
metabisulfite, sodium bisulfate, butylated 
hydroxyltoluene, and tocopherol. (2) 
g) Humectants: Intranasal moisture is important for 
preventing dehydration. Therefore, humectants can be 
added mostly in gel-based nasal products to avoid 
irritation of the nasal cavity. Humectants do not affect 
drug absorption. Examples like glycerin, sorbitol, and 
mannitol. (2) 
h) Absorption enhancer: Absorption enhancers could 
also be needed when a drug has poor membrane 
permeability, large molecular size, lack of lipophilicity 
and enzymatic degradation. Once a suitable enhancer is 
identified, its optimal concentration should be 
experimentally determined. Generally, higher 
concentrations of absorption enhancers are probable to 
result in nasal irritation and damage to the nasal mucosa. 
On the other hand, lower enhancer concentrations would 
generally provide lower or no improvement of 
absorption. (2) 
i) Osmolarity: Isotonic solutions are administered for 
shrinkage of the nasal epithelial mucosa, because of the 
effect of osmolarity on the absorption, this results in 
increased permeation of the compound because of 
structural changes in the compound. Isotonic solutions 
also are known to inhibit ciliary activity. (4) 
j) Viscosity: The higher viscosity of the formulation 
increases contact time between the drug and 
therefore the nasal mucosa, thereby increasing 
permeation time. At the same time,  formulations 
with high viscosity can affect the normal functions 
like ciliary beating or muco-ciliary clearance and 
thus changes the permeability of drugs.  (4) 
3. Physiological factors 
a) Blood flow/ supply: Nasal mucosa has a larger 
surface area and rich with blood supply which makes 
nasal an optimum place for drug absorption. The 
blood flow influences significantly the systemic nasal 
absorption of the medicine so that because 
it enhances more drug passes through the 
membrane, reaching the overall circulation.(2)  
b) Nasal secretion: The mucus layer probably exists as a 
double layer (5 mm thick) consisting of a periciliary 
sol phase in which the cilia beat and a superficial 
blanket of gel are moved forwards by the tip of the 
cilia. The permeability of drug through the nasal 
mucosa is suffering from viscosity of nasal secretion. 
Approximately 1.5-2.1 ml of mucus is produced daily 
in the nasal cavity. It is reported that if the sol layer 
of mucus is too thin, the viscous surface layer will 
inhibit the ciliary beating, and if the sol layer is too 
thick, mucociliary clearance is impaired because 
contact with cilia is lost. The solubility of a drug in 
nasal secretions: a drug needs to be solubilized 
before it permeates. Various studies revealed that 
the secretion ad clearance rates are reduced at night 
thus altering the permeation of drug. In such cases, 
chronokinetics will dictate the pattern and rate of 
permeation. (2) 
c) Nasal cycle: In this process congestion and relaxation 
regulate the rise and fall in the amount of drug 
permeation process. (2) 
d) A  pH of the nasal cavity: Nasal cavity pH in the adult is 
5.5-6.5 and 5.0-7.0 in infants. A greater drug permeation 
is usually achieved at a nasal pH that is lower than the 
drug‟s pKa because under such conditions the penetrant 
molecules exist as unionized form. A change in the pH of 
mucus can affect the ionization and thus increase or 
decrease the permeation of drugs, depending on the 
nature of the drug. The ideal pH of a formulation should 
be within 4.5–6.5 and if possible the formulation should 
also have the buffering capacity. (2) 
e) Effect of mucociliary clearance: The main function of 
the mucociliary clearance system is to remove foreign 
substances (bacteria, allergens and so on) and particles 
from the nasal cavity, thus preventing them from 
reaching the lower airways. Normal mucociliary transit 
has been reported to be 12 to 15 min. Transit times of 
more than 30 min are considered to be abnormal and are 
indicative of impaired mucociliary clearance. Reduced 
Mucociliary clearance (MCC) and ciliary beating (MCC) 
increases the time of contact between a drug and the 
mucous membrane and subsequently enhances drug 
permeation; whereas, increased MCC decreases drug 
permeation. Some factors affecting MCC like drugs, 
hormonal changes of the body, pathological conditions, 
environmental conditions, and formulation factors.(4) 
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f) Effect of deposition on absorption: Deposition of the 
formulation in the anterior portion of the nose provides 
an extended nasal residence and better absorption, and 
this is an area of low permeability, whereas, in the 
posterior portion of the nose, where the drug 
permeability is generally higher, the deposited drug is 
eliminated by mucociliary clearance and therefore has a 
shorter residence time. (4) 
g) Effect of enzymatic activity: Many enzymes might 
affect the stability of drugs that are present on the nasal 
mucosa. For example, proteins and peptides are 
subjected to degradation by proteases and 
aminopeptidases at the mucosal membrane. (4) 
4. Biological Factors: Efforts have been made to modify 
and explore the structural features and mechanism of 
nasal mucosa to increase its permeability, this is usually 
not available in the normal physiology of the nasal cavity, 
mainly during chronic application. These alterations 
could cause unintended adverse effects and result in 
pathological implications.  
a) Structural features: Nasal epithelium mainly consists of 
different types of cells that show variety in nasal 
absorption and because of other factors such as 
presences of microvilli, cell density, surface area, and 
several cells. The respiratory region is most accurate and 
suitable for permeation of the compounds.(2) 
b) Biochemical changes: A large number of enzymes such 
as oxidative and conjugative enzymes, peptidases and 
proteases are mainly acted on nasal mucus which is an 
enzymatic barrier for the delivery of drugs. These 
enzymes are responsible for the degradation of drugs in 
the nasal mucosa and result in the creation of a pseudo-
first-pass effect, which hampers the absorption of drugs. 
Some example like the nasal P450-dependent 
monooxygenase system has been implicated in nasal 
metabolism of nasal decongestants, alcohols, nicotine, 
and cocaine.(2) 
5. Pathological condition: Diseases such as the common 
cold, rhinitis, atopic rhinitis and nasal polyposis are 
usually associated with mucociliary dysfunctioning, hypo 
or hypersecretions, and irritation of the nasal mucosa, 
which can influence drug permeation.  
a) Environmental condition: Temperatures in the range 
of 24°C cause a moderate reduction in the rate of MCC. A 
linear increase in ciliary beat frequency occurs with an 
increase in temperature, which in turn influences the 
properties of the mucous membrane. (4) 
DIFFERENT METHODS TO IMPROVE NASAL 
ABSORPTION 
1) Permeation enhancers: A variety of permeation 
enhancers have been investigated to improve the nasal 
absorption, like fatty acids, bile salts, phospholipids, 
surfactants, cyclodextrin, etc., which act via different 
mechanisms such as inhibition of enzyme activity, 
reduction of mucus viscosity, decreasing muco-ciliary 
clearance, opening tight junctions, and solubilizing or 
stabilizing the drug. 
2) Prodrug approach: Prodrugs are the inactive chemical 
moiety that becomes active at the target site. This 
approach is mainly used to improve physicochemical 
properties such as taste, solubility, and stability of the 
formulation. This approach includes the derivatization of 
C and N termini, esters, and cyclic prodrugs. 
3) In situ gel: The conversion into a gel by the influence of 
stimuli including temperature, pH, and ionic 
concentration, is possible with substances like Carbopol, 
cellulose derivatives, lecithin, chitosan, etc. These 
formulations generally control the problems of 
administration. 
4) Nasal enzyme inhibitors: Enzyme inhibitors like 
protease and peptidase are used as inhibitors for the 
formulation of peptide and protein molecules. Other 
examples are bile salts, amastatin, bestatin, boroleucine, 
fusidic acids, etc.  
5) Structural modification: Drug structure can be 
modified without changing the pharmacologic activity, to 
improve nasal absorption. Chemical modifications are 
mainly used to modify the physicochemical properties of 
the drug such that they lead to improved nasal 
absorption of the drug. 
6) Mucoadhesion: Mucoadhesion is defined as the state in 
which two materials are held together for a long period. 
Mucoadhesive polymers make contact with the biological 
membrane, and after the establishment of contact, they 
penetrate the tissue surface. Natural polymers can be 
easily obtained from natural sources, and require an 
environmentally- friendly method of processing at a low 
cost. Some examples include potato starch, rice starch, 
maize starch, wheat starch, guar gum, tragacanth, 
xanthan gum, etc. Synthetic polymers have high cost of 
production and also produce environmental pollution 
during synthesis. These polymers include polyethylene 
oxide, polyvinyl alcohol, methylcellulose, ethylcellulose, 
hydroxyl propylmethylcellulose, etc. (4) 
INTRANASAL FORMULATIONS AND THEIR 
LIMITATIONS 
A myriad of intranasal formulations is available that include 
nasal drops, solution sprays, suspension sprays, emulsions, 
powders, ointments, gels, liposomes, microspheres, and 
nanoparticles. These non-mucoadhesive formulations 
administered in a limited volume of 25-200 μl exhibit short 
residence time due to mucociliary clearance. Consequently, 
the half-life of clearance for both liquid and powder 
formulations is of the order of 15 -30 min. This is mainly due 
to the mucus which moves through the nose at a rate of 5-6 
mm/min resulting in particle clearance within the nose, 
about every 12-15 min. This limits the time available for 
drug absorption from the applied dosage form and results in 
poor nasal bioavailability. To prevent rapid mucociliary 
clearance and improve the bioavailability of drugs, there is a 
persistent need for the development of the controlled-
release delivery system. Mucoadhesive nasal drug delivery 
systems can be looked on as a viable option that can adhere 
to the nasal mucosa, will increase the residence time within 
the nasal cavity, intensify the contact between the nasal 
mucosa and the drug, increase the drug concentration at the 
site of deposition and facilitate drug absorption to enhance 
bioavailability. (4)(7) 
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Figure 3: Various forms of nasal formulations. 
THE ADVANTAGES OF IN SITU NASAL GELS OVER 
OTHER NASAL FORMULATIONS INCLUDE: 
 Reduction in post-nasal drip into the back of the throat 
and therefore minimization of bad taste problems and 
loss of drug from the nasal cavity. 
 Reduction in anterior leakage of the drug out of the 
nasal cavity. 
 Localization of formulation on the mucosa thereby 
providing a better chance for the drug to be absorbed. 
 Gels can afford the use of soothing agents or emollients 
which may not be suitable for solutions, suspensions or 
powder dosage form so can reduce irritation potential. 
 It can be developed for both systemic and local 
delivery, and a precise dose can be administered by the 
use of a metered-dose nasal actuator system. 
 Prolong drug release 
 Reduced systemic side effect 
 Reduced number of application 
 Ease of administration 
 Reduced frequency of administration 
 Better patient compliance (5)(7) 
 IN SITU GEL 
In Latin, in situ means ‘in position’ or ‘in its original 
place’. For the past 30 years, greater attention has been 
directed towards the development of controlled and 
sustained drug delivery systems. A vast amount of 
research has been carried out in designing polymeric 
systems such as in situ gels. In situ gel formation of drug 
delivery systems can be defined as a liquid 
Formulationgenerating a solid or semisolid depot after 
administration. In situ activated gel, forming Systems 
are those which are when exposed to physiological 
conditions that will shift to a gel phase. This new 
concept of manufacturing a gel in situ was suggested for 
the first time in the early 1980s. Gelation occurs via the 
cross-linking of polymer chains that can be achieved by 
covalent bond formation (chemical cross-linking) or 
Non-covalent bond formation (physical cross-linking). 
The routes of administration for in situ gel could be oral, 
ocular, rectal, vaginal, injectable and intra-peritoneal. 
“Gel” is that the state which exists in between liquid and 
solid, which consists of physically crosslinked networks 
of long polymer molecules, with liquid molecules 
trapped within a three-dimensional polymeric network 
swollen by a solvent. This system is a liquid aqueous 
solution before the administration and a gel at 
physiological conditions. Prolonged and sustained 
release of the drug is reproducible, and the in situ gel is 
biocompatible, with magnificent stability and reliable 
quantities of medication, making it more accurate. There 
are various routes for in situ gel drug delivery, for 
example, oral, ocular, vaginal, rectal, intravenous, 
intraperitoneal, etc. In situ gel is a new dosage form that 
has been applied in nasal drug delivery recently. 
Compared with other liquid nasal formulations, nasal in 
situ gels are administered as low viscosity solutions into 
the nasal cavity, and upon contact with the nasal 
mucosa, the polymer changes conformation producing a 
gel, so it cannot only prolong the contact time between 
the drug and also the absorptive sites within the cavity 
but also release drug slowly and continuously,  
hence, it's especially useful for those drugs used 
chronically. The phase transition can be induced by a 
shift in pH, a shift in temperature or by the presence of 
cations. (4)(5)(8) 
IMPORTANCE OF IN SITU GELLING SYSTEM 
The major importance is that the possibility of administering 
accurate and reproducible quantities compared to already 
formed gel. It increases the exposure time of drugs with that 
of mucus at the site of absorption and has better 
bioavailability, increases patient compliance. (4) 
PRINCIPLE OF IN SITU GELLING SYSTEM 
The principle of in situ gelling system is of solid nasal 
formulations are that the nasal formulations absorb the 
nasal fluid after administration and form a gel within the 
cavity. The foreign body sensation can avoid by the 
formation of nasal gel within the cavity. Due to bioadhesive 
nature, the gel adheres to the nasal mucosa. It acts as a 
release controlling matrix and thus acts as a sustained drug 
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and goes around the cilia, forward in the propulsion phase, 
backward in the preparatory phase. At the propulsion phase, 
cilia extremity scrapes the upper layer of mucus penetrating 
it almost 0.5 mm. ciliary activity zones then occur at various 
intervals. Cilia are situated backward which helps to remove 
any obstacle if there is any intervention in the propulsion 
phase. After the formation of the gel, dissolution occurs and 
or the mucociliary removal to the nasopharynx occurs. 
Therefore there is no need to remove the dosage form after 
it has been depleted of a drug. (4)(9) 
PROPERTIES OF NASAL IN- SITU GEL   
 It should have a long residence time.  
 It should be low viscous.  
 Free-flowing allows for reproducible administration to 
the nasal cavity.  
 The nasal in-situ gel follows the phase transition 
mechanism and shear forces in nasal cavity wall. (10) 
APPROACHES OF IN-SITU GELLING SYSTEM:  
Various approaches for an in-situ gelling system,  
A) Stimuli Responsive In-Situ Gelling System 
1. Temperature induced in-situ gel system. 
2. pH induced in-situ gel systems.  
B) Osmotically Induced In-Situ Gelling System  
C) Chemically Induced In-Situ Gelling System  
1. Ionic cross linking.  
2. Enzymatic cross linking.  
3. Photo- polymerization.  
D)In situ formation based on the physical mechanism- 
A) Stimuli Responsive In-Situ Gelling System  
Physical or chemical changes in response to small external 
changes in the environmental conditions 
1. Temperature induced in-situ gel system:  
Temperature is the most generally used stimulus in 
environmentally responsive polymer systems. The change 
of temperature isn't only relatively easy to regulate, but 
also easily applicable both in-vivo and in-vitro. These in-
situ gelling systems are liquid at temperature (20˚-25˚C) and 
further undergoes gelation when it comes in contact with 
body fluids (35˚-37˚C) because of an increase in 
temperature. Polymers like poloxamers or pluronics, 
cellulose derivatives (methylcellulose, HPMC, ethyl 
(hydroxyl ethyl) cellulose (EHEC) and xyloglucan show 
temperature induced gelation. 
The ambient and physiologic temperature is the important 
temperature range for such a system, such that experimental 
management is facilitated and for gelation there is no 
requirement of an external source of heat. A temperature 
sensitive in situ gel undergoes a sol-gel phase transition at a 
critical temperature, specifically at the lower critical solution 
temperature (LCST) or upper critical solution temperature 
(UCST). LCST polymers form a hydrophilic-to-hydrophobic 
transition with the increasing temperature. LCST polymers 
include poly (N-isopropyl acrylamide), poly (N,N-dimethyl 
acrylamide), poly(vinyl ether), poly(N-vinylalkylamide), 
polyphosphazene derivatives, and poly(ethylene oxide)-b-
poly(propylene oxide). UCST polymers show a hydrophobic-
to-hydrophilic transition with increasing temperature. UCST 
polymers include polyacrylamide/ polyacrylic acid 
interpenetrating polymer networks. 
2. pH-Triggered systems 
The pH is also another important environment-sensitive 
parameter for drug delivery, because the change in pH 
occurs at many specific sites or pathologic body sites, like 
the stomach, intestine, endosome, vagina, blood vessels, 
lysosome, and tumor extracellular sites. The polymers 
containing acidic or alkaline functional groups that respond 
to changes in pH are called pH-sensitive polymers. All pH-
responsive polymers contain suspended acidic or basic 
groups that also accept or release protons in response to 
changes in environmental pH. Polyelectrolytes are known as 
polymers with a large number of ionizable groups'. The pH is 
the main signal, which can be addressed through pH-
responsive materials. Gelling of the solution is induced by a 
change in pH. At pH 4.4 the formulation is free from is a free 
running solution that undergoes coagulation when the pH is 
raised by the body fluid to pH 7.4. The polymers which show 
pH-induced gelation are cellulose and its derivatives 
polyvinyl acetate, polyethylene glycol. As the external pH 
increases, swelling of the hydrogel increases in the case of 
weakly acidic groups, but decreases when the polymer 
contains weakly  (basic) groups. Examples: Anionic pH-
responsive polymers are based on 
–– Poly (acrylic acid), (Carbopol) 
–– Polyvinyl acetal diethylaminoacetate solutions form 
hydrogels at a neutral pH condition at pH 4, with a low 
viscosity. 
–– Other examples are Polymethacrylic acid, Polyethylene 
glycol, Cellulose acetate phthalate  latex, Pseudolatexes, etc 
B) Osmotically Induced In-Situ Gelling System: In this 
system, gelling of the solution is triggered by changes in 
ionic strength. It is considered that the rate of gelation 
depends on the osmotic gradient across the surface of the 
gel. The aqueous solution of polymer forms a clear solution 
which forms a clear gel in the presence of cation like the 
mono or divalent cations. The polymer like gellan gum, 
alginates shows osmotically induced gelation.  
C) Chemically Induced In-Situ Gelling System: The 
chemical reaction which forms in-situ gel systems are ionic 
crosslinking, enzymatic cross linking and photo-
polymerization 
1. Ionic cross linking: Ion sensitive polymers like 
carrageenan, gellan gum, pectin, sodium alginate undergo 
phase change with the presence of various ions mainly like 
k+, Ca2+, Na+ ions. These polymers categorize into the class 
of ion-sensitive ones. For example, Alginic acid undergoes 
phase transition in the presence of divalent cations example-
Ca2+ because of the interaction with a guluronic acid block 
in alginate chains.  
2. Enzymatic cross-linking: In-Situ formation catalyzed by 
natural enzymes has not been investigated widely but this 
system has some advantages over other approaches. For 
example, an enzymatic process performs effectively under 
physiologic conditions without the need for potentially 
harmful chemicals like monomers and initiators.  
3. Photo polymerization: This system when introduced to 
the desired site with injection gets photocured in-situ with 
the help of fiber optic cables and then drug release for a 
prolonged period of time from the system. A 
photopolymerization, biodegradable hydrogels as a tissue 
contacting material and controlled release carrier.  
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D) In situ formation based on the physical mechanism-  
1. Swelling – 
In situ formation can also occur when water absorbed by 
the material from the surrounding environment and 
expands to occur desired space. The substance like 
myverol 18-99 (glycerol monooleate), which contain polar 
lipid that swells in water to make lyotropic liquid 
crystalline phase structures. It has some bioadhesive 
properties and may be degraded invivo by enzymatic 
action. 
2. Diffusion- 
This method involves the diffusion of the solvent into the 
surrounding tissue from a polymer solution and leads 
to precipitation or solidification of the polymer matrix. N-
methyl pyrrolidone (NMP) solvent is beneficial for this 
type of system. (2)(5)(4)(6)(11) 
METHODS OF FORMULATION 
1. Cold Method: 
In this method, the drug is stirred with a sufficient quantity 
of double distilled water and kept overnight at 4°C in a 
refrigerator. The in situ gelling polymers are then added 
slowly with stirring. The dispersion is stored in a 
refrigerator till a clear solution is formed and finally volume 
is adjusted with distilled water. This method is chosen when 
poloxamer, chitosan or carbopol is used as a gelling polymer. 
Considering the fact that polymeric dispersion of poloxamer 
is in solution at lower temperature and gets converted into a 
gel at higher nasal temperature because the solubility of 
polypropylene oxide chain of poloxamer decreases at a high 
temperature which results in precipitation or salting-out of a 
polymer. Similarly, chitosan also requires the low 
temperature to remain as a solution at room temperature, its 
hydrophobicity increases with an increase in 
temperature.(7) 
2. Hot Method:  
This method is used when gellan gum or pectin is used as a 
gelling polymer. At high temperature, gellan chains dissolve 
in water and assume a random-coil conformation with high 
segmental mobility at high temperatures and remain as a 
solution at a higher temperature. A phase transition occurs 
on a cooling gellan gum solution in the presence of ions like 
K+ or Ca2+. Similarly, pectin also requires a high 
temperature for its demethoxylation, which helps in the 
formation of a solution or dissolving of pectin. (7) 
Other methods of preparation:  
A) Solution polymerization/cross linking  
B) Suspension polymerization  
C) Polymerization by irradiation  
D) Chemically cross-linked hydrogels  
E) Physically cross-linked hydrogels  
A) Solution Polymerization/Crosslinking  
Ionic monomer or neutral monomer and multifunctional 
crosslinking agents are mixed in the solution for 
copolymerization reaction. UV light or redox initiator system 
is used for thermally initiate the polymerization reaction. In 
the polymerization reaction, solvent work as a heat link, and 
decrease problems related to temperature control. Distilled 
water is used to remove the unreacted monomers, 
crosslinking agents and initiators which are used to form the 
hydrogels. By using this method one can synthesize a great 
different variety of in-situ gels.  
B) Suspension Polymerization  
Spherical hydrogel microparticles with a size range of 1μm 
to 1mm are prepared by the suspension polymerization 
method. In the non-solvent solution, the monomer solution 
is dispersed to form fine droplets and a stabilizer is added in 
this solution to stabilize the fine droplets. Thermal 
decomposition of free radicals is used to initiate 
polymerization. Unreacted monomers, crosslinking agents 
and initiators are removed by washing from prepared 
microparticles. This method is used to prepare the hydrogel 
microparticles of polyvinyl alcohol.  
c) Polymerization by Irradiation  
Hydrogels of unsaturated compounds are formed by using 
high energy radiation like gamma and electron beams. 
Radicals on the polymer chain are formed by irradiation of 
aqueous polymer solution. Covalent bonds are formed by the 
recombination of the macroparticles on the different chains 
and thus forms a cross-linked structure. Polymerization of 
macroparticles can interact with oxygen during radiation 
and to avoid it, inert atmosphere radiation is performed by 
using nitrogen and argon gas. Examples of polymers 
crosslinked by radiation method involve polyvinyl alcohol, 
polyethylene glycol, and polyacrylic acid.  
d) Chemically Crosslinked Hydrogels  
Polymers having functional groups like –OH, -COOH, -NH2, is 
soluble in water and hydrogels are prepared by forming a 
covalent linkage between the polymer chains and 
complementary reactivity, such as amine-carboxylic acid due 
to the presence of functional groups. Hydrogels of polymers 
containing –OH groups like polyvinyl alcohol are prepared 
by using glutaraldehyde as a crosslinking agent. Due to the 
addition, reactive functional groups present on the polymer 
reacts with the crosslinking agent. Unreacted agents have to 
be extracted because these agents are highly toxic. Organic 
solvents are used to carry out the reaction and water can 
react with the crosslinking agent. After the formation of 
hydrogels, the drug is loaded on this and released as the 
first-order release.  
e) Physically Crosslinked Hydrogels  
The covalent crosslinking agent is known to be toxic. 
Reversible ionic crosslinking is utilize to overcome this 
problem and to form hydrogels. The formation of a network 
through ionic bridges between the polymeric chains occurs 
when chitosan reacts with a positively charged component 
like ions or molecules. It is a simple and mild procedure. 
Auxiliary molecules like catalysts are not required in 
contrast to covalent crosslinking. Polyelectrolyte complex 
with polyacrylic acid can be formed by chitosan polymer. (9) 
POLYMER USED IN IN-SITU GEL: 
1. The polymers and their degradation products should be 
nontoxic and non-absorbable from the gastrointestinal tract. 
2. It should adhere quickly to the moist tissue and should 
possess some site-specificity. 
3. It should not irritate the mucous membranes. 
4. It should possess a wide safety margin both locally and 
systemically. 
5.The value of the polymer should be not too high so that the 
prepared dosage form remains Competitive. (2) 
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DIFFERENT POLYMERS USED FOR THE 
PREPARATION OF IN-SITU GELLING SYSTEM:  
A) Polymer used for pH-sensitive In-situ gelling system 
a) Carbopol: Carbopol polymers are having excellent water 
sorption property. Carbopol polymer swell in water up to 
1000 times by its original volume and 10 times their original 
diameter to form a gel when exposed to a pH environment 
above 4.0-6.0 because the pKa of those polymers is 6.0 ± 0.5. 
It is a high relative molecular weight, a cross-linked 
polyacrylic acid derivative and has a strong Mucoadhesive 
property. If there’s an addition of cellulose then it’ll reduce 
polymer concentration and improve a gelling property. 
Carbopol 934 and Carbopol 981 are mostly used as gelling 
agents. The Mucoadhesive property is due to electrostatic 
interaction or hydrophobic interaction, hydrogen bonding. It 
is an acidic molecule. When dispersed in water, the 
carboxylic group of the molecule partially dissociates and 
forms a coil. As it is a pH-sensitive polymer, an increase in 
the pH of the solution results in swelling of the polymer. The 
gelling effect is started with two stages, neutralization of 
solution by addition of, sodium hydroxide.(2) 
B) Polymer used for temperature-sensitive In-situ 
gelling system 
a) Poloxamer: Poloxamer is a water-soluble tri-block 
copolymer consisting of two polyethylene oxide and 
polypropylene oxide core in an ABA configuration. 
Poloxamer is also known as pluronic. Poloxamer has good 
thermal setting property and increased residence time of the 
drug. It acts as a gelling agent and solubilizing agent. 
Poloxamer gives colorless, transparent gel. Depending on the 
ratio and distribution of hydrophilic and hydrophobic chain 
different molecular weights are available and it has different 
gelling properties. It consists of central polypropylene oxide 
surrounded by polyethylene oxide. At temperature (25ᵒ C), it 
acts like a viscous liquid and it gets transformed to form a 
transparent gel when temperature increases (37ᵒC). It forms 
a small micellar subunit in solution and increases in 
temperature results increase in viscosity result in swelling 
to make large micellar cross-linked network at a lower 
temperature.(2) 
b) Xyloglucan 
Xyloglucan is obtained from tamarind seeds and is 
composed of a (1-4)-β-D-glucan backbone chain, which has 
(1-6)-α-D xylose branches that are partially substituted by 
(1-2)-β-D-galactoxylose. When its partially degraded by β- 
galactosidase, the obtained product exhibits thermally 
reversible gelation by the lateral stacking of the rod-like 
chains. The temperature of phase transition sol-gel 
transition varies with the degree of galactose elimination. It 
forms the thermally reversible gels on warming to body 
temperature. Xyloglucan has the main application in oral 
delivery exploits the proposed slow gelation time (several 
minutes) that might allow in-situ gelation within the 
stomach following the oral administration of chilled 
xyloglucan solution. Xyloglucan gels mainly used for oral, 
intraperitoneal, ocular and rectal drug delivery.(2)(12) 
c)Chitosan 
Chitosan is obtained by alkaline deacetylation of chitin, a 
natural component of shrimp and crab shell. Chitosan has a 
biodegradable, thermosensitive, polycationic polymer. 
Chitosan is a pH-dependent cationic polymer. Chitosan has 
biocompatible property, which remains dissolved in 
aqueous solutions up to a pH of 6.2. Neutralization of 
aqueous solution of chitosan to a pH exceeding up to 6.2 
leads to the formation of a hydrated gel-like precipitate. The 
pH gelling cationic polymer solution is transformed to the 
thermally sensitive pH-dependent gel-forming aqueous 
solutions, in absence by chemical changes by the addition of 
polyol salts bearing one anionic head like glycerol, sorbitol, 
fructose or glucose phosphate salts to chitosan aqueous 
solution.(11)(7) 
C)Polymer used for ion-sensitive In-situ gelling system-  
a) Sodium alginate: sodium alginate is a salt of alginic acid. 
It is extracted from brown algae. It has a linear block 
polysaccharide containing two type monomers β-D-
Mannuronic acid and α-L glucuronic acid residues connected 
by 1,4 glycosidic linkages. Sodium alginate biodegradable 
and non-toxic which exhibit good mucoadhesive property 
due to the presence of the carboxylic group.  The mechanism 
of polymer is the monomers of alginate β-D-Mannuronic acid 
and α-L glucuronic acid are arranged as M-M block with 
altering sequence (M-G) block. Upon interaction of G block of 
polymer with calcium, moieties give in the formation of a gel. 
On G: M ratio the mechanical strength and porosity of 
hydrogel depends, type of crosslinker used and 
concentration of alginate polymer solution.(5) 
b)Gellangum 
Gellan gum polymer is an anionic deacetylated exocellular 
polysaccharide obtained by Pseudomonas elodea with a 
tetrasaccharide repeating unit of one α-L rhamnose, one β-
D-glucuronic acid, and two β-D-glucuronic acid residues. 
Gellan gum has the property of gelation which is both 
temperature-dependent or cations induced. This gelation 
process involves the formation of double-helical junction 
zones followed by aggregation of the double-helical 
segments to make a three-dimensional network by 
complexation with cations and hydrogen bonding with 
water. The formulation consisted of a gellan solution with 
calcium chloride and sodium citrate complex. When 
administered orally, the calcium ions are released in the 
acidic environment of the stomach leading to gelation of 
gellan thus forming a gel in situ. In situ gelling gellan 
formulation as a vehicle for oral delivery of theophylline is 
reported.(5) 
c) Pectin 
Pectins are a family of polysaccharides, in which the 
backbone of polymer mainly contains α-(1-4)-D-galacturonic 
acid residues. Low methoxy pectins (degree of esterification 
<50%) readily form gels in aqueous solution in the presence 
of free calcium ions, which crosslink the galacturonic acid 
chains in a manner described by the egg-box model. 
Although the gelation of pectin will occur in the presence of 
H + ions, a source of divalent ions, generally calcium ions is 
required to produce the gels that are suitable as vehicles for 
drug delivery. The main advantage of using pectin for these 
formulations is that it is water-soluble, so organic solvents 
are not necessary for the formulation. Divalent cations 
present in the stomach, carry out the transition of pectin to 
gel state when it is administered orally. Calcium ions in the 
complex form may be included in the formulation for the 
induction of pectin gelation.(11)(7) 
d) Xanthum gum 
Xanthan gum is a high molecular weight extracellular 
polysaccharide produced by the fermentation of the gram-
negative bacterium Xanthomonas campestris. The primary 
structure of this naturally produced cellulose derivative 
contains a cellulosic backbone (β- D-glucose residues) and a 
trisaccharide side chain of β-D-mannose-β-D-glucuronic 
acid-α-D-mannose attached with alternate glucose residues 
of the main chain. The anionic character of this polymer is 
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due to the presence of both glucuronic acid and pyruvic acid 
groups in the side chain.(11) 
EVALUATION PARAMETERS OF NASAL IN-SITU 
GELS  
1) Clarity: The clarity of in situ gel is find out by visual 
inspection under the black and white background.(2) 
2)  Sol-gel transition temperature and gelling time: 
For In-Situ gel-forming systems, the sol-gel transition 
temperature and pH should be determined. Gelling 
time is the time required for the first detection of 
gelation of the in-situ gelling system. Thermosensitive 
in-situ gel should be checked for in-situ gelling at body 
temperature.(2)(11) 
3)  Gelling capacity: Mix in-situ gel with simulated nasal 
fluid (in the proportion of 25:7 i.e. application volume 
25μl and volume of nasal fluid in the nasal is 7 μl) to 
find out the gelling capacity of the ophthalmic product. 
The gelation may be assessed visually by noting the 
time for and time is taken for the dissolution of the 
formed gel. (2) 
4) Viscosity: The viscosity and rheological properties of 
the polymeric formulations, either in solution or in a 
gel made with artificial tissue fluid and may be 
determined with different viscometers like Brookfield 
viscometer, cone, and plate viscometer. The viscosity of 
these formulations should be such that it should be 
patient compliance.(2)  
5) Texture analysis: The firmness, consistency, and 
cohesiveness of formulation may be determined using 
a texture analyzer which mainly indicates the syringe 
ability of sol so the formulation can easily be 
administered in-vivo.(2) 
6) In vitro drug release studies: For in-situ formulations 
to be administered by oral, ocular, or intranasally the 
drug release studies are carried out with the plastic 
dialysis cell. The cell is made up of the two-
compartment, a donor compartment and a receptor 
compartment. Both cells are separated with the help of 
the cellulose membrane. The formulation is placed in 
the donor compartment. The specific volume of the 
receptor solution can be removed at specific time 
intervals and replaced with the fresh media. This 
receptor solution is analyzed for the drug release using 
an analytical method.(2) 
7) Sterility testing: Sterility testing is carried out as per 
the IP 1996. Incubate the formulation for not less than 
14days at 300˚-350˚C in the fluid thioglycolate medium 
to find the growth of bacteria and at 200˚-250˚C in 
soyabean casein digest medium to find the growth of 
fungi in the formulation. (2) 
8) Accelerated stability studies: Formulation is 
replaced in amber-colored vials and sealed with 
aluminum foil for the short term accelerated stability 
at 40˚±20˚C and 75±5% RH as per ICH state guidelines. 
(2) 
9)  Appearance: Insitu nasal gel is examined visually for 
clarity in sol and gel form. (9) 
10)  pH of gel: With the help of a pH meter pH of in situ 
nasal gel is measured. (9) 
11)  Measurement of Gelation Time: 2 ml of formulation 
gel is taken in a test tube and kept in an oven at 37° C 
temperature. At specific time gelation of in situ gel is 
examined.(11) 
12) Critical Ionic Concentration (CIC):  
Critical ionic concentration was an important parameter of 
ionic in situ gel, indicating the minimum ionic concentration 
that promoted phase transition. Simulated nasal fluid (SNF) 
was prepared: 8.77 g NaCl, 2.98 g KCl, and 0.59 g CaCl2 were 
dissolved in 1 L distilled water. In 1 mL of in situ gel 
solution, artificial nasal fluid was mixed in an ampoule, 
respectively. After 30 s, the gels are adhered to the bottom of 
bottles without flowing, shows that the gels formed. The 
normal physiological temperature of the human nasal cavity 
is 32°C–34°C. All measurements were taken at 34°C and 
made in triplicate.(13) 
13) Water Holding Capacity: 
1 ml of the formulation was accurately transferred and put 
in a centrifuged EP tube that had been accurately 
weighed.250 µL of artificial nasal fluid was then added and 
mixed, respectively. The gel quality was accurately weighed 
and recorded as W0. This gel was centrifuged for 10 min at 
8000 rpm, and the separate water layer was blotted by filter 
papers. The final gel quantity was weighed accurately and 
recorded as W. All measurements were taken at 34°C and 
tested in triplicate.(13) 
Water holding capacity = 
 
  
 × 100%. 
14) Volume Expansion Coefficient: 
1 mL of In situ gel was removed accurately into a graduated 
test tube, in that 250µL of artificial simulated nasal fluid was 
added and mixed it, and volume was recorded as 1.25 mL. 2 
mLsimulated artificial nasal fluid was added and then in situ 
gel was formed after phase changes; the final volume was 
recorded as VT. Therefore, the volume of the gel after phase 
transition was VG, VG = VT-2.0. Each sample was tested three 
times at 34°C. The expansion coefficient, S%, of the gel was 
described as:(13) 
S% =  
      
  
      
15) Nasal Mucociliary Transport Time 
To compare the residence time of in situ gel in the nasal 
cavity the method is a physiological saline solution 
containing methylene blue dye at a concentration of 5 
mg/mL and formulation in situ gel with the same methylene 
blue content were prepared. By intramuscular injection of 
sodium thiopental (7 mg/mL) rats (n = 5) were anesthetized. 
10 µL of each sample was infiltrated into the right nostril of 
the rat using a micropipette, respectively. By using wet 
cotton swabs the throats of the rats were wiped, and the 
appearance time of the blue dye was recorded. Each sample 
was examined in triplicate.(13) 
16) In Vitro Mucoadsorption Strength: 
It is the force required to separate the nasal mucosa and 
formulations. By using an improved physical balance 
method the in vitro bioadhesion was measured. Briefly, fresh 
goat nasal mucosa obtained from the local slaughterhouse 
was transported in PBS (phosphate-buffered saline, pH 7.4) 
and used within 5 h. The nasal cavity was cut longitudinally 
along the nasal septum, and the nasal mucosa with a 
thickness of 0.6 mm was separated from the nasal olfactory 
area. The two mucosas were fixed to the openings of the two 
same glass vials by cyanoacrylate adhesive combined with 
thin wire; the mucosa side was outward, and the exposed 
area of the nasal cavity film was A (cm2). An empty 
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polyethylene bag was connected at one end of the balance 
scale, and the bottom of one of the glass bottles was 
connected at the other end, with the bottle mouth 
downward. The second glass bottle mouth was upward, as 
for the lifting platform, to balance gravity. On the mucous 
membrane of the glass bottle below 50 mg gel was evenly 
distributed, and the height of the lifting platform was 
adjusted to make the mucous membrane come into contact 
with the gel of the two glass bottles, and the balance was in 
the equilibrium position. A certain force was applied to 
make both sides contact each other and the gel for 2 min. On 
another site of balance dropwise water was added to the 
empty polyethylene tape. The weight of the water (m) was 
recorded when the mucosa was separated from the gel. The 
experiment was performed in triplicate.  By the following 
formula the in vitro mucoadsorption strength was obtained: 
Detachment Stress = 
   
 
 
where m is the weight added to the balance in grams; g is the 
acceleration due to gravity (taken as 980 cm.s-2); A is the 
surface area of the mucosal tissue in cm2.(13) 
17) TEM and SEM: 
A small quantity of formulation was placed on the carbon 
film after dilution and dried for 12 h naturally. By using 
scanning electron microscopy the morphology of a 
formulation was studied. The formulation was lyophilized 
and then sprayed with gold for the observation.(13) 
18) Drug content determination: 
The vials containing the formulation were shaken for 2–3 
min manually and 100 µL of the preparation was transferred 
to 25 ml volumetric flasks with a micropipette and the final 
volume was made up with phosphate buffer pH 6.2. The 
amount of drug was determined using UV–vis 
spectrophotometer (UV 2600, Chemito, India).(8) 
19) Gel strength determination: 
Gel strength is expressed in terms of in seconds required by 
a 35g piston for penetration of 5cm distance, from the 50g 
gel formulation. This test was performed using the ‘Gel 
strength apparatus’ modified at the laboratory. Gel (50g) 
was placed in a 100 ml measuring cylinder. Gelation was 
induced by SNF. The apparatus for measuring gel strength 
(weight:35g) was then placed onto the gel. The gel strength 
was measured as the time (in seconds) required moving the 
apparatus 5 cm down through the gel. (8) 
20) Ex vivo permeation study:  
Fresh nasal tissues were obtained from the nasal cavity of 
sheep the local slaughterhouse. A piece of the nasal mucosa 
was mounted as a flat sheet in a two-chamber diffusion cell 
maintained at 37 ± 0.5◦C with the mucosal side facing the 
donor compartment. Phosphate buffer pH 7.4 was placed in 
the receptor compartment. After a preincubation time of 20 
min, 2 mL formulations were placed on the mucosal surface 
in the donor compartment. Gelation was induced by 
simulated nasal fluid. At a predetermined time interval, 0.5 
ml samples were withdrawn from the receiver compartment 
and replacing the sampled volume with phosphate buffer pH 
7.4 after each sampling, for a period of 10 h. Samples so 
withdrawn were suitably diluted and analyzed 
spectrophotometrically (UV 2600, Chemito, India) at a 
specific wavelength. Permeability coefficient (p) in cm/h 
was calculated by the following formula: 
                                          p = 
      
   
 
where dQ/dt is flux or permeability rate (mg/h), C0 is the 
initial concentration of drug in the donor compartment and 
A is the effective surface area of the nasal mucosa. The 
cumulative of salbutamol sulphate permeated per unit area 
was plotted against time, and the slope of the linear portion 
of the plot was used as a steady-state flux, dQ/dt.(8) 
21)  Histopathological studies: 
Histopathological studies were performed on isolated nasal 
mucosa obtained from the sheep. The nasal mucosa tissues 
were carefully removed from the nasal cavity of sheep 
obtained from the local slaughterhouse. Tissues were 
immediately used after separation. The evaluation of tissue 
incubated in phosphate buffer (pH 6.2) was compared with 
tissue incubated in the diffusion chamber of Franz cell with 
in situ gel formulations. Tissue was fixed in 10% buffered 
formalin (pH 6.2), routinely processed, and embedded in 
paraffin after these paraffin sections were cut and stained 
with hematoxylin and eosin. The sections were examined by 
optical microscopy (Motic, China), to examine the 
morphological changes to the tissue by a pathologist blinded 
to the study. (8) 
22) Fourier transform infrared spectroscopy and 
thermal analysis:  
During the gelation process, the nature of interacting forces 
can be evaluated using this technique by employing the 
potassium bromide pellet method. (11)  
23) Thermogravimetric analysis:  
Thermogravimetric analysis is used for the formulation of 
forming polymeric systems to quantitate the percentage of 
water in the hydrogel.(2) 
24) Differential Scanning Calorimetry: 
Differential scanning calorimetry is used to check if there are 
any changes in thermograms as compared with the pure 
ingredients and excipients used thus indicating the 
interactions. DSC thermograms of the formulation (stored at 
40 ± 2°C/75% ± 5% RH for 2 months) were recorded. All the 
samples were placed into sealed aluminum pans and 
scanned at a heating rate of 10°C min-1 over the 









Sabale et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2020; 10(2-s):183-197 
ISSN: 2250-1177                                                                                  [196]                                                                                 CODEN (USA): JDDTAO 
Table 4: In situ gelling systems 
Sr.no Stimulus responsive agent Triggering 
factor 
Drug  Category Year Ref 
1 Gellan Gum Ionic Huperzine  Antialzimers 2006 (14) 
     2008 (15) 
2 Gellan Gum Ionic Metoclopramide 
Hydrochloride  
Antiemetic 2010 (16) 
3 Chitosan Thermal Ropinirole Antiparkinsons 2010 (17) 
4 Carbopol 934 pH  Zolmitriptan Antimigraine 2013 (18) 
5 Poloxomer407, 
Poloxomer 188 
Thermal Rasagiline Antiparkinsons 2013  
6 Pluronic PF127 Thermal Curcumin Antialzimers 2013 (19) 
7 Gellan Gum Ionic Sumatriptan Antimigraine 2013 (20) 
8 Pluronic PF127 Thermal Levodopa Antiparkinsons 2013 (21) 
9 Pluronic PF127 Thermal Tramadol 
Hydrochloride 
Antidepressant 2014 (22) 
10 Chitosan Thermal Doxepine Antidepressant 2014 (23) 
11 PF-127 Hydrochloride Phenylephrine 
Hydrochloride 
Antiallergic Rhinitis  2016 (24) 
12 Gellan Gum Ionic Salbutamol Sulphate Antiasthmatic  2016 (8) 
13 Poloxomer 407 Thermal Timolol Maleate Antihypertensive 2016 (25) 
14 Pluronic PF127 Thermal Ropinirole Antiparkinsons 2016 (26) 
15 Pluronic PF127 Thermal Amantidine Antiparkinsons 2016 (27) 
16 Poloxomer 188 Thermal  Fluticasone 
Propionate 
Antiallergic rhinitis 2017 (28) 
17 Poloxomer 407, 
Poloxomer 188 
Thermal Geniposide Neurodegenerative 2017 (29) 
18 Gellan Gum Ionic Lorazepam Antiepileptic 2017 (30) 
19 Gellan Gum Ionic Fluoxitine 
Hydrochloride 
Antidepressant 2017 (31) 
20 Pluronic PF127 Thermal Revastigmine Antialzimers 2017 (32) 
21 Pluronic PF127 Thermal Agomelatine Antidepressant 2017 (33) 
22 Poloxomer 188 Thermal Nortriptyline 
Hydrochloride 
Antidepressant 2017 (34) 
23 Pluronic PF127 Thermal Revastigmine 
Hydrogen Tartrate 
Antialzimers 2017 (35) 
24 Carbopol 934 pH Paliperidone Antischizophrenic 2017 (36) 
25 Poloxomer 407 Thermal Montelukast  
Sodium  
Antiasthmatic 2018 (37) 
27 Gellan Gum Ionic  Donepezil 
Hydrochloride 
Antialzimers 2018 (38) 
28 Gellan Gum Ionic Chromolyn Sodium Antiasthmatic 2019 (39) 
29 Carbopol 934 pH Zolpidem Insomnia 2019 (40) 
30 Gellan Gum Ionic Paeonol Antiparkinsons 2019 (13) 
31 Gellan Gum Ionic Resveratrol Antialzimers 2019 (41) 
32 Gellan Gum Ionic Resveratrol Antialzimers 2016 (42) 
 
CONCLUSION 
Nasal drug delivery is fast emerging field as an alternative 
route for the administration of drugs and biomolecules that 
are susceptible to enzymatic or acidic degradation, undergo 
first pass hepatic metabolism, are incompletely absorbed in 
the GIT or produce undesirably slow effects when 
administered orally. Nasal route circumvents bioavailability 
issues associated with listed factors and also offers the 
advantage of controlled drug delivery for extended periods 
of time. The success of a controlled release product is 
directly linked to patient compliance which in situ gels can 
offer. Exploitation of polymeric in situ nasal gels for 
controlled release of drug provides numerous advantages 
over conventional dosage forms and can be considered as 
reliable and non-invasive drug delivery system. Exploration 
of novel gel triggering mechanisms and use of water-soluble, 
biodegradable polymers for product development of the in 
situ nasal gel formulations makes them more acceptable. 
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